| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
5,473 |
5,211 |
$1.54M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
7,273 |
6,931 |
$339K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
3,414 |
3,237 |
$304K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
953 |
905 |
$287K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,344 |
1,269 |
$103K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,390 |
3,218 |
$67K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,758 |
1,671 |
$46K |
| 87486 |
|
1,086 |
1,034 |
$36K |
| 87581 |
|
1,085 |
1,033 |
$36K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
198 |
195 |
$34K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
206 |
203 |
$32K |
| 87640 |
|
1,088 |
1,027 |
$32K |
| 99000 |
|
1,819 |
1,721 |
$30K |
| 87541 |
|
892 |
842 |
$30K |
| 80053 |
Comprehensive metabolic panel |
2,619 |
2,491 |
$25K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
864 |
860 |
$16K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
2,193 |
2,072 |
$12K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
46 |
44 |
$12K |
| 84443 |
Thyroid stimulating hormone (TSH) |
1,104 |
1,087 |
$11K |
| 99001 |
|
659 |
623 |
$10K |
| 80061 |
Lipid panel |
1,183 |
1,169 |
$9K |
| 80074 |
|
198 |
197 |
$7K |
| 84481 |
|
503 |
498 |
$6K |
| G0659 |
Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes |
1,756 |
1,694 |
$5K |
| 87529 |
|
179 |
162 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
772 |
768 |
$5K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
226 |
211 |
$4K |
| 84439 |
|
728 |
720 |
$4K |
| 0071A |
|
51 |
50 |
$4K |
| 82607 |
|
417 |
416 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
121 |
117 |
$3K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
93 |
64 |
$3K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
188 |
174 |
$3K |
| G0410 |
Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes |
8,898 |
1,122 |
$3K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
188 |
174 |
$3K |
| 87631 |
|
21 |
20 |
$2K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
184 |
174 |
$2K |
| 87481 |
|
57 |
51 |
$2K |
| 82746 |
|
167 |
167 |
$2K |
| 90832 |
Psychotherapy, 30 minutes with patient |
584 |
471 |
$1K |
| 87653 |
|
27 |
27 |
$1K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
60 |
60 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
31 |
30 |
$953.87 |
| 87511 |
|
153 |
146 |
$906.21 |
| 0072A |
|
17 |
17 |
$821.63 |
| 0002A |
|
25 |
25 |
$810.12 |
| 87500 |
|
69 |
63 |
$734.02 |
| 87641 |
|
69 |
63 |
$589.81 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
111 |
105 |
$533.23 |
| 87430 |
|
30 |
29 |
$483.24 |
| 83655 |
|
37 |
37 |
$421.31 |
| 82728 |
|
39 |
39 |
$400.75 |
| 84480 |
|
31 |
30 |
$378.40 |
| 0001A |
|
36 |
36 |
$207.00 |
| 84436 |
|
31 |
30 |
$183.88 |
| 90791 |
Psychiatric diagnostic evaluation |
28 |
28 |
$173.72 |
| 83540 |
|
28 |
28 |
$157.56 |
| 81001 |
|
73 |
70 |
$135.12 |
| 36415 |
Collection of venous blood by venipuncture |
1,944 |
1,757 |
$43.92 |
| 82550 |
|
14 |
13 |
$5.20 |
| 81003 |
|
12 |
12 |
$2.16 |
| G0177 |
Training and educational services related to the care and treatment of patient's disabling mental health problems per session (45 minutes or more) |
369 |
57 |
$0.00 |
| 96156 |
|
52 |
52 |
$0.00 |